ABL2 and small cell lung carcinoma: To determine whether lung cancer cells containing ABL2 amplifications are sensitive to ABL inhibitors, we utilized two lung adenocarcinoma cell lines (H810 and H1355) and a small cell lung cancer cell line (H1048), all harboring ABL2 amplifications, and subjected to treatment with imatinib.